| 000 | 04218cam a2200409Ii 4500 | ||
|---|---|---|---|
| 001 | 95858 | ||
| 003 | ES-MaUEC | ||
| 005 | 20230102112725.0 | ||
| 006 | m o d | ||
| 007 | cr cnu|||unuuu | ||
| 008 | 170426s2017 sz a o 000 0 eng d | ||
| 020 |
_a3319532359 _q(electronic bk.) |
||
| 020 |
_a9783319532356 _q(electronic bk.) |
||
| 020 | _z3319532332 | ||
| 020 |
_z9783319532332 _q(print) |
||
| 040 |
_aGW5XE _cGW5XE _dN$T _dEBLCP _dYDX _dUAB _dMERER _dESU _dAZU _dUPM _dIOG _dOCLCF _dOCLCO _dCOO _dOCLCQ _dOCLCO _dOCLCA _dVT2 _dOTZ _dOCLCO _dOCLCQ _dOCLCA _dU3W _dOCLCO _dES-MaUEC _bspa |
||
| 050 | 4 |
_aRC271.R3 _b2017 EB |
|
| 066 | _c(S | ||
| 245 | 0 | 0 |
_aAdvances in radiation oncology _cJeffrey Y.C. Wong, Timothy E. Schultheiss, Eric H. Radany, editors. |
| 264 | 1 |
_aCham, Switzerland _bSpringer International Publishing _c2017 |
|
| 300 |
_a1 recurso en línea (viii, 271 páginas) _bilustraciones (algunas a color) |
||
| 336 |
_aTexto _btxt _2rdacontent |
||
| 337 |
_aelectrónico _bc _2rdamedia |
||
| 338 |
_arecurso electrónico _bcr _2rdacarrier |
||
| 347 |
_atext file _bPDF _2rda |
||
| 490 | 0 |
_aCancer treatment and research _x0927-3042 _vvolume 172 |
|
| 505 | 0 |
_6880-01 _aUse of Multi-parametric MRI in Radiotherapy -- MRI Guided Radiotherapy -- MRI Guided Focused Ultrasound and Thermal Oncology -- Use of PET and Novel Molecular Imaging in IGRT -- The Impact of IGRT on Normal Tissue Toxicity -- Image Guided Brachytherapy -- Hypofractionated IGRT for the treatment of primary cancers -- SBRT and the treatment of oligometastatic disease -- Molecular and image guided systemic targeted radiotherapy -- Integrating Radiotherapy and Immunotherapy -- Biomarkers and Radiotherapy -- Application of Mathematical and Systems Biology to Radiotherapy -- The Importance of Cancer Stem Cells in Radiotherapy -- Targeting DNA repair mechanisms in radiotherapy. |
|
| 520 | 3 | _aThis book concisely reviews important advances in radiation oncology, providing practicing radiation oncologists with a fundamental understanding of each topic and an appreciation of its significance for the future of radiation oncology. It explores in detail the impact of newer imaging modalities, such as multiparametric magnetic resonance imaging (MRI) and positron emission tomography (PET) using fluorodeoxyglucose (FDG) and other novel agents, which deliver improved visualization of the physiologic and phenotypic features of a given cancer, helping oncologists to provide more targeted radiotherapy and assess the response. Due consideration is also given to how advanced technologies for radiation therapy delivery have created new treatment options for patients with localized and metastatic disease, highlighting the increasingly important role of image-guided radiotherapy in treating systemic and oligometastatic disease. Further topics include the potential value of radiotherapy in enhancing immunotherapy thanks to the broader immune-stimulatory effects, how cancer stem cells and the tumor microenvironment influence response, and the application of mathematical and systems biology methods to radiotherapy. | |
| 650 | 7 |
_aCancer _xImaging. _2fast _0(OCoLC)fst00845381 _9139308 _0comprobar BNE19900970859 |
|
| 700 | 1 |
_aRadany, Eric H., _eeditor literario |
|
| 700 | 1 |
_aSchultheiss, Timothy E., _d1951- _eeditor literario |
|
| 700 | 1 |
_aWong, Jeffrey Y. C., _eeditor literario |
|
| 856 | 4 | 0 |
_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-53235-6 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid) |
| 880 | 0 |
_6505-01/(S _aPreface; Contents; 1 Combining Radiotherapy and Immunotherapy; Abstract; 1 Radiation Therapy Effects on the Immune System; 1.1 Immunostimulatory Activity of Radiation Therapy; 1.2 Immunosuppressive Effects of Radiation Therapy; 2 Pre Clinical and Clinical Combinations of Radiotherapy and Immune Agents; 2.1 Toll-like Receptor (TLR) Agonists; 2.2 Cancer Vaccines; 2.3 GM-CSF; 2.4 TGF-β Antagonist; 2.5 CTLA-4 Blockade; 2.6 PD-1/PD-L1; 3 Optimizing Radiation Dose and Fractionation; 4 Future Directions; 4.1 CSF-1/CSF-1R; 4.2 OX40; 5 Conclusion; References. |
|
| 988 | _aSpringer_Medicine_2017 | ||
| 998 |
_b02/2018 _dz _e- _zSI |
||
| 999 |
_c95858 _d95858 _x1 |
||